Загрузка...

2025 Henlius R&D Day

With hundreds of brilliant minds gathered, we shared our evolving innovation pipeline, exchanged insights on the next wave of biotech and biopharma, and imagined what’s next for patients worldwide. Here’s a glimpse of the momentum we’re building.

Видео 2025 Henlius R&D Day канала Henlius
Комментарии отсутствуют
Зарегистрируйтесь или войдите с
Информация о видео
17 апреля 2025 г. 12:35:26
00:00:59
Henlius
Правообладателям
Жалоба на материал Недопустимый материал Нарушение авторских прав
Комментарии
Поделиться
Другие видео канала

Henlius and Saudi Arabia’s SVAX signed a strategic partnershipHenlius and Saudi Arabia’s SVAX signed a strategic partnership

Differentiated Characteristics in Molecular Structure and MOA of SerplulimabDifferentiated Characteristics in Molecular Structure and MOA of Serplulimab

Fierce Biotech: Inside Henlius’ Global Growth StrategyFierce Biotech: Inside Henlius’ Global Growth Strategy

Advancing HER2+ GC treatmentAdvancing HER2+ GC treatment

Henlius to Showcase Latest Results of Serplulimab at 2024 ASCOHenlius to Showcase Latest Results of Serplulimab at 2024 ASCO

HLX43: PD-L1 targeting ADC MechanismHLX43: PD-L1 targeting ADC Mechanism

Henlius and Sermonix Announce Strategic CollaborationHenlius and Sermonix Announce Strategic Collaboration

Henlius 2023 Annual ResultsHenlius 2023 Annual Results

Henlius' 2025 H1 Results AnnouncedHenlius' 2025 H1 Results Announced

We define a partner of choice, and we desire to become yours.We define a partner of choice, and we desire to become yours.

2023 H1 Financial Highlights2023 H1 Financial Highlights

Henlius Releases 2022 ESG ReportHenlius Releases 2022 ESG Report

Henlius 2024 Annual Results: RMB820M Net Profit, +50% YoYHenlius 2024 Annual Results: RMB820M Net Profit, +50% YoY

Henlius to Release Clinical Data at 2024 ASCO GIHenlius to Release Clinical Data at 2024 ASCO GI

HANSIZHUANG Combined with Chemotherapy for the First-line Treatment of sqNSCLCHANSIZHUANG Combined with Chemotherapy for the First-line Treatment of sqNSCLC

Henlius Enters Exclusive License Agreement with Lotus for Anti-PD-1 mAb Serplulimab in South KoreaHenlius Enters Exclusive License Agreement with Lotus for Anti-PD-1 mAb Serplulimab in South Korea

Henlius and Convalife Reach Global Strategic Cooperation on NeratinibHenlius and Convalife Reach Global Strategic Cooperation on Neratinib

EMA Validates Henlius and Organon Filing for Another Self-developed Biosimilar CandidateEMA Validates Henlius and Organon Filing for Another Self-developed Biosimilar Candidate

Henlius is honored to showcase the latest resultsfrom clinicaltrials at #ESMO Asia 2024 in SingaporeHenlius is honored to showcase the latest resultsfrom clinicaltrials at #ESMO Asia 2024 in Singapore

Henlius to Present Latest Clinical Data of HLX10 and HLX22 at 2025 ASCO GIHenlius to Present Latest Clinical Data of HLX10 and HLX22 at 2025 ASCO GI

Яндекс.Метрика
© 2008-2026 «Информационно-развлекательный портал города Верхняя Салда»
salda.ws@mail.ru salda_ws Контакты Карта портала Сообщить об ошибке Соглашения Пользовательское соглашение Соглашение о конфиденциальности Согласие на обработку персональных данных Информация для правообладателей Об использовании Cookies
Все заметки Новая заметка Страницу в заметки
Страницу в закладки Мои закладки
На информационно-развлекательном портале SALDA.WS применяются cookie-файлы. Нажимая кнопку Принять, вы подтверждаете свое согласие на их использование.
О CookiesНапомнить позжеПринять